X0202 SCHEDULE 13G/A 0001425738 XXXXXXXX LIVE 6 Common Stock, $0.0001 par value per share 03/31/2026 0001623526 Stoke Therapeutics, Inc. 86150R107 45 Wiggins Ave Bedford MA 01730 Rule 13d-1(c) Redmile Group, LLC DE 0.00 4164120.00 0.00 4164120.00 4164120.00 N 6.7 IA OO The information in Item 4 relating to the shares of the Issuer's common stock ("Common Stock") that are or may be deemed beneficially owned by Redmile Group, LLC ("Redmile") is incorporated herein by reference. Percentage based on 62,240,347 shares of Common Stock outstanding as of March 31, 2026, as reported by the Issuer in its Definitive Proxy Statement on Schedule 14A filed with the SEC on April 22, 2026 (the "Schedule 14A"). Jeremy C. Green X0 0.00 4164120.00 0.00 4164120.00 4164120.00 N 6.7 HC IN The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Jeremy C. Green is incorporated herein by reference. Percentage based on 62,240,347 shares of Common Stock outstanding as of March 31, 2026, as reported by the Issuer in the Schedule 14A. Redmile Biopharma Investments III, L.P. DE 0.00 3505612.00 0.00 3505612.00 3505612.00 N 5.6 PN Percentage based on 62,240,347 shares of Common Stock outstanding as of March 31, 2026, as reported by the Issuer in the Schedule 14A. Stoke Therapeutics, Inc. 45 Wiggins Ave, Bedford, MA 01730 Redmile Group, LLC Jeremy C. Green Redmile Biopharma Investments III, L.P. Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 Redmile Biopharma Investments III, L.P. c/o Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom Redmile Biopharma Investments III, L.P.: Delaware Y Redmile Group, LLC - 4,164,120 (1) Jeremy C. Green - 4,164,120 (1) Redmile Biopharma Investments III, L.P. - 3,505,612 Redmile Group, LLC - 6.7% (2) Jeremy C. Green - 6.7% (2) Redmile Biopharma Investments III, L.P. - 5.6% (2) Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments III, L.P. - 0 Redmile Group, LLC - 4,164,120 (1) Jeremy C. Green - 4,164,120 (1) Redmile Biopharma Investments III, L.P. - 3,505,612 Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments III, L.P. - 0 Redmile Group, LLC - 4,164,120 (1) Jeremy C. Green - 4,164,120 (1) Redmile Biopharma Investments III, L.P. - 3,505,612 (1) As of March 31, 2026, Redmile's and Jeremy C. Green's beneficial ownership of Common Stock is comprised of 4,164,120 shares of Common Stock. All of such shares of Common Stock are directly owned by certain investment vehicles, including Redmile Biopharma Investments III, L.P., for which Redmile is the investment manager (the "Redmile Funds"). Redmile may be deemed to beneficially own these securities in its capacity as the investment manager with discretion to vote and dispose of all shares of Common Stock held by the Redmile Funds. Mr. Green also may be deemed to beneficially own these securities as the principal of Redmile. Redmile and Mr. Green each disclaim beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such securities, if any. (2) Percentage based on 62,240,347 shares of Common Stock outstanding as of March 31, 2026, as reported by the Issuer in the Schedule 14A. Y Y N See the response to Item 4. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Redmile Group, LLC /s/ Jeremy C. Green 05/15/2026 Jeremy C. Green /s/ Jeremy C. Green 05/15/2026 Redmile Biopharma Investments III, L.P. /s/ Jeremy C. Green 05/15/2026